Video
Expert forum on prostate cancer survivorship: Individualized care
Author(s):
“We certainly need to move away from a model of care that is follow up driven by tumor markers or imaging alone,” says Netty Kinsella, RN, MSc, PhD.
Video Player is loading.
In this video, Netty Kinsella, RN, MSc, PhD, and Jai Seth, MD, BSc, MSc, discuss the importance of individualized care in prostate cancer survivorship. This discussion is part of a larger forum on prostate cancer survivorship with Marta Skrodzka, MD, PhD, FEBU, FECSM, FEAA. Skrodzka is a consultant urologist and Seth is a urology consultant at St George’s University Hospital, and Kinsella is a uro-oncology nurse consultant at the Royal Marsden NHS Foundation Trust in London, United Kingdom.
Related Videos
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
Selecting Between Receptor Pathway Inhibitors for mHSPC
The Use of Ultra-Low PSA in Specific Patient Profiles
Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Fred Saad, MD, FRCS, reacts to FDA approval of darolutamide in mCSPC
Using Ultrasensitive PSA Assays in Routine Practice
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
Related Content
